Skip to content

Joseph Zohar

6 papers in the library · 19 citations · publishing 2014-2026

Papers

Sort Most recent Most cited

MDMA as an early post-trauma intervention in a translational animal model of PTSD.

Progress in Neuro-Psychopharmacology and Biological Psychiatry July 24, 2026 Omer Baruch, Nadav Reiss, Doron Todder et al.

Post-traumatic stress disorder (PTSD) remains difficult to prevent after trauma, highlighting the need for early interventions that reduce the risk of chronic symptom development. This controlled study investigated the preventive potential of 3,4-methylenedioxymethamphetamine (MDMA) in a validated rat model of PTSD induced by predator scent stress (PSS). Adult male Sprague-Dawley rats (N = 175)...

Acute pretrauma ethanol exacerbates PTSD-like phenotype in rats and is reversed by early intranasal ketamine

Scientific Reports June 14, 2026 Bar Eilat Yogev, Gal Levi, Noa Efroni et al.

Alcohol consumption before trauma is a prevalent but understudied risk factor for posttraumatic stress disorder (PTSD). This study investigated whether acute ethanol exposure prior to trauma modulates PTSD-like symptom development in rats, identified hippocampal mechanisms involved, and tested an early post-trauma intervention. Adult male Sprague-Dawley rats received ethanol (1.6 g/kg, 40% v/v,...

Global Perspectives on CNS Drug Innovation: Achievements, Barriers, and Priorities for the Next Decade

The International Journal of Neuropsychopharmacology May 5, 2026 Hiroyuki Uchida, Gabriella Gobbi, Joseph Zohar et al.

BACKGROUND: Over the past decade, neuropsychopharmacology has shifted from stagnation to momentum, with first-in-class mechanisms and biomarker-enabled trials spanning psychiatry and neurology. METHODS: We narratively synthesized advances from 2013 to 2026 across central nervous system (CNS) discovery and development, including pivotal trials, regulatory actions, digital/real-world evidence,...

DOI: 10.1093/ijnp/pyag023 (opens in new tab) Neuropsychopharmacology Mandate Neuroactive steroid Clinical neuroscience +5

Impact of subanesthetic ketamine delivered via AmyloLipid nanovesicle (ALN)-based intranasal system on biobehavioral responses in an animal model of PTSD

Translational Psychiatry March 25, 2026 Gal Levi, Amnon Sintov, Joseph Zohar et al.

Ketamine holds promise for the treatment of post-traumatic stress disorder (PTSD), but challenges remain in delivery and sustained effects. This controlled study evaluates a novel intranasal formulation, employing AmyloLipid nanovesicles (ALN) to enhance ketamine’s therapeutic efficacy in a predator-scent stress (PSS) rat model of PTSD. A total of 130 rats underwent PSS or sham-PSS exposure,...

MDMA treatment paired with a trauma-cue promotes adaptive stress responses in a translational model of PTSD in rats

Translational Psychiatry May 3, 2022 Shira Arluk, Michael A. Matar, Lior Carmi et al. 19 citations

AbstractMDMA (3,4-methylenedioxymethamphetamine), a synthetic ring-substituted amphetamine, combined with psychotherapy has demonstrated efficacy for the treatment of chronic posttraumatic stress disorder (PTSD) patients. This controlled prospective study aimed to assess the bio-behavioral underpinnings of MDMA in a translational model of PTSD. Rats exposed to predator-scent stress (PSS) were...

Blunting of the HPA-axis underlies the lack of preventive efficacy of early post-stressor single-dose Delta-9-tetrahydrocannabinol (THC).

Pharmacology, Biochemistry, and Behavior July 2014 Tzur Alexander Mayer, Michael Alex Matar, Zeev Kaplan et al.

The therapeutic value of Delta-9-tetrahydrocannabinol (Δ9-THC) in the aftermath of trauma has recently raised interest. A prospective animal model for posttraumatic stress disorder was employed to assess the behavioral effects of a single dose of Δ9-THC administered intraperitoneally following exposure to psychogenic stress. Animals were exposed to predator scent stress and treated 1h later...

DOI: 10.1016/j.pbb.2014.04.014 (opens in new tab) Full text (opens in new tab) Animal model Cb1 antagonist/inverse agonist Delta-9-Tetrahydrocannabinol δ9-THC Early drug intervention +2